Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 27;21(15):5338.
doi: 10.3390/ijms21155338.

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?

Mauro Giorgi  1 , Silvia Cardarelli  2 , Federica Ragusa  3 , Michele Saliola  1 , Stefano Biagioni  1 , Giancarlo Poiana  1 , Fabio Naro  2 , Mara Massimi  3
Affiliations
Review

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?

Mauro Giorgi et al. Int J Mol Sci. .

Abstract

In March 2020, the World Health Organization declared the severe acute respiratory syndrome corona virus 2 (SARS-CoV2) infection to be a pandemic disease. SARS-CoV2 was first identified in China and, despite the restrictive measures adopted, the epidemic has spread globally, becoming a pandemic in a very short time. Though there is growing knowledge of the SARS-CoV2 infection and its clinical manifestations, an effective cure to limit its acute symptoms and its severe complications has not yet been found. Given the worldwide health and economic emergency issues accompanying this pandemic, there is an absolute urgency to identify effective treatments and reduce the post infection outcomes. In this context, phosphodiesterases (PDEs), evolutionarily conserved cyclic nucleotide (cAMP/cGMP) hydrolyzing enzymes, could emerge as new potential targets. Given their extended distribution and modulating role in nearly all organs and cellular environments, a large number of drugs (PDE inhibitors) have been developed to control the specific functions of each PDE family. These PDE inhibitors have already been used in the treatment of pathologies that show clinical signs and symptoms completely or partially overlapping with post-COVID-19 conditions (e.g., thrombosis, inflammation, fibrosis), while new PDE-selective or pan-selective inhibitors are currently under study. This review discusses the state of the art of the different pathologies currently treated with phosphodiesterase inhibitors, highlighting the numerous similarities with the disorders linked to SARS-CoV2 infection, to support the hypothesis that PDE inhibitors, alone or in combination with other drugs, could be beneficial for the treatment of COVID-19.

Keywords: PDE; SARS-CoV-2; cAMP; cGMP; coronavirus; cytokine storm; fibrosis; inflammation; pan-selective inhibitors; pneumonia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
The scheme highlights the different pathologies currently treated with phosphodiesterase inhibitors that are in common with disorders linked to severe acute respiratory syndrome corona virus 2 (SARS-CoV2) infection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cyranoski D. Mystery deepens over animal source of Coronavirus. Nature. 2020;579:18–19. doi: 10.1038/d41586-020-00548-w. - DOI - PubMed
    1. Shang J., Wan Y., Luo C., Ye G., Geng Q., Auerbach A., Li F. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 2020;117:11727–11734. doi: 10.1073/pnas.2003138117. - DOI - PMC - PubMed
    1. Tai W., He L., Zhang X., Pu J., Voronin D., Jiang S., Zhou Y., Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel Coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol. Immunol. 2020;17:613–620. doi: 10.1038/s41423-020-0400-4. - DOI - PMC - PubMed
    1. Baden L.R., Rubin E.J. COVID-19: The search for effective therapy. N. Engl. J. Med. 2020;382:1851–1852. doi: 10.1056/NEJMe2005477. - DOI - PMC - PubMed
    1. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect. 2020;80:607–613. doi: 10.1016/j.jinf.2020.03.037. - DOI - PMC - PubMed

MeSH terms

Substances